Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q2 2019 Earnings Conference Call - Final Transcript
Aug 08, 2019 • 05:00 pm ET
Good day, ladies and gentlemen, and welcome to the Q2 2019 Aclaris Therapeutics, Inc. Earnings Conference Call. At this time all participants are in a listen-only mode. Following management's prepared remarks, we will host a question-and-answer session. [Operator Instructions] As a reminder, this conference call may be recorded.
It is now my pleasure to hand the conference over to Ms. Kamil Ali-Jackson, Chief Legal Officer. Ma'am, you may begin.
Thank you. I'm Kamil Ali-Jackson, Chief Legal Officer for Aclaris. Please note that earlier today, Aclaris issued its press release announcing second quarter 2019 results. For those of you who have not yet seen it, you will find a release posted in the Investors section of our website at www.aclaristx.com. Joining me today for the call are Dr. Neal Walker, President and Chief Executive Officer; Dr. Stuart Shanler, our Chief Scientific Officer, Frank Ruffo, our Chief Financial Officer; Dr. David Gordon, our Chief Medical Officer, and Jeff Wayne, our Interim Head of Commercial.
Before we begin our prepared remarks, I would like to remind you that various statements we make during this call about the company's future results of operations and financial position, business strategy and plans and objectives for Aclaris' future operations are considered forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties that could cause actual results to differ materially from those reflected in such statements.
These risks are described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of Aclaris' Form 10-K for the year ended December 31st, 2018, Form 10-Q for the quarter ended June 30th, 2019 filed today and other filings Aclaris makes with the SEC from time to time. These documents are available under the SEC filings section of the Investors page of Aclaris' website at www.aclaristx.com. All of the information we provide on this conference call is provided as of today and we undertake no obligation to update any forward-looking statements, we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. A link to the webcast is posted in the Investors section of our website.
I'll now turn the call over to Dr. Neal Walker, President and CEO of Aclaris. Neal?
Neal S. Walker
Thank you, Kamil, and thank you everyone for joining us on our Q2 earnings call today. The second quarter has both been rewarding, but also challenging. In June, we reported encouraging interim six-month data from our uncontrolled open-label AGA or androgenetic alopecia study. This pilot study was designed to assess the safety and efficacy of the use of topical JAK inhibitors in a new and highly prevalent indication called male and female pattern hair loss. We will have the 12-month data by year-end and if it is consistent with the 6-month data, the next step would be to find a strategic partner